勘误：ANKRD44基因沉默：在人表皮生长因子受体2（Her2）样乳腺癌曲妥珠单抗耐药中的潜在作用。
Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
出版信息
Front Oncol. 2019 Jul 18;9:709. doi: 10.3389/fonc.2019.00709. eCollection 2019.
Abstract
[This corrects the article DOI: 10.3389/fonc.2019.00547.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2019.00547。]
相似文献
1
Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.勘误：ANKRD44基因沉默：在人表皮生长因子受体2（Her2）样乳腺癌曲妥珠单抗耐药中的潜在作用。
Front Oncol. 2019 Jul 18;9:709. doi: 10.3389/fonc.2019.00709. eCollection 2019.
2
ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.ANKRD44基因沉默：在人表皮生长因子受体2（Her2）样乳腺癌曲妥珠单抗耐药中的潜在作用
Front Oncol. 2019 Jun 26;9:547. doi: 10.3389/fonc.2019.00547. eCollection 2019.
3
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.TGFBI 的表观遗传沉默赋予人乳腺癌对曲妥珠单抗的耐药性。
Breast Cancer Res. 2019 Jul 5;21(1):79. doi: 10.1186/s13058-019-1160-x.
4
Erratum: The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis.勘误：去泛素化酶UCHL1通过促进游离脂肪酸合成诱导HER2阳性乳腺癌对多柔比星产生耐药性。
Front Oncol. 2021 Apr 14;11:687249. doi: 10.3389/fonc.2021.687249. eCollection 2021.
5
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.勘误：HER2阳性乳腺癌新辅助曲妥珠单抗化疗后基线和残留肿瘤中的PAM50亚型：来自单一机构的连续系列研究。
Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019.
6
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.内收蛋白 A2 促进 HER2 阳性乳腺癌中 HER2 的内化和对曲妥珠单抗为基础的治疗的敏感性。
Breast Cancer Res. 2017 Oct 3;19(1):110. doi: 10.1186/s13058-017-0900-z.
7
Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.内在的HER2 V777L突变介导一名乳腺癌患者对曲妥珠单抗的耐药性。
Med Oncol. 2017 Jan;34(1):3. doi: 10.1007/s12032-016-0857-2. Epub 2016 Nov 29.
8
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.河马通路转导蛋白YAP1/TEAD在HER2阳性乳腺癌中诱导对曲妥珠单抗的获得性耐药。
Cancers (Basel). 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108.
9
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Yes1信号传导介导乳腺癌对曲妥珠单抗/拉帕替尼的耐药性。
PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017.
10
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.Epha5 通过调节癌症干细胞样特性介导曲妥珠单抗耐药的 HER2 阳性乳腺癌。
FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8.
Zotero 插件